Antibacterial resistance pattern among Escherichia coli strains isolated from Mansoura hospitals in Egypt with a special reference to quinolones
Abstract
Extensive use of fluoroquinolone antibacterial in clinical practice has been associated with increasing frequency of quinolone-resistant Escherichia coli strains. In the current study, a total of 80 E. coli clinical isolates from Mansoura hospitals patients in Egypt were studied for antibacterial susceptibility pattern against 15 different antibacterials. These strains were tested for quinolones resistance by minimum inhibitory concentration (MIC) determination using broth micro-dilution method. The resistance rate of ciprofloxacin and levofloxacin for E. coli isolates was found to be 60%. PCR was performed for detection of plasmid-mediated quinolone resistance genes including qnrA, qnrB and qnrS. 30 and 61.3% of E. coli isolates were positive for qnrA and qnrB, respectively, whereas qnrS was identified in only 15% of isolates. Quinolone resistance-determining region (QRDR) of gyrA and ParC genes was characterized for 17 ciprofloxacin and levofloxacin resistant E. coli isolates (MIC 12.5-200 µg mL-1). Two mutation sites in gyrA were detected in 17 tested E. coli isolates. However, two mutation sites in parC were detected in four E. coli isolates. The amino acid change at Ser-83 and aspartic-87 in GyrA were the most common mutation sites identified in the isolates. These results indicated that multiple mechanisms of quinolone-resistance are commonly found in E. coli isolated from Mansoura hospitals. Key words: Quinolone resistance, gyrA, parC, qnr gene.
Read the paper
Related studies
- Deciphering the Resistome of the Widespread Pseudomonas aeruginosa Sequence Type 175 International High-Risk Clone through Whole-Genome Sequencing
- Laboratory-based nationwide surveillance of antimicrobial resistance in Ghana
- Phenotypic characterization of an international Pseudomonas aeruginosa reference panel: strains of cystic fibrosis (CF) origin show less in vivo virulence than non-CF strains
- Incidence and factors associated with development of phlebitis: results of a pilot study cohort
- Efficacy of triple therapy with a proton pump inhibitor, levofloxacin, and amoxicillin as first-line treatment to eradicate Helicobacter pylori
- Ten-Day versus 14-Day Levofloxacin-Containing Triple Therapy for Second-Line Anti-Helicobacter pyloriEradication in Taiwan
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.